Inherited platelet disorders represent a heterogeneous group of genetic conditions that affect the number, size, or function of platelets, with clinical manifestations ranging from mild mucocutaneous ...

Thrombocytopenic disorders include numerous causes of decreased platelet production or increased platelet destruction. Having too few platelets can lead to internal or serious bleeding after surgery ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

A new miniature 3D model of human bone marrow has just been described. The model may help clinicians predict which patients will benefit from a new therapy for blood platelet disorders, such as ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

SAN ANTONIO, Nov. 10, 2025 – A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer’s disease decades ahead of time, allowing for possible ...

Even as biomedical engineer Anirban Sen Gupta refines artificial platelets to stem traumatic bleeding, he and his colleagues are seeking new uses for their synthetic solution. The latest application ...

Please provide your email address to receive an email when new articles are posted on . A 65-year-old male presented for his annual exam. The medical assistant (MA) checking the patient in remarked ...

Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...